Spleen Preserving Surgery for Splenic Hydatidosis: A Cohort Study on Short and Long-Term Outcomes

Minimally Invasive Surgery Clinical Trial

Official title:

Minimally Invasive Spleen Preserving Surgery to Treat Primary Splenic Hydatidosis: Short and Long Term Outcomes: A Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06289816
• Other study ID #: 28/01/2023
• Status: Completed
• Start date: January 1, 2015
• Est. completion date: June 30, 2021

Study information

• Verified date: February 2024
• Source: Yarmouk University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This retrospective cohort study examines the effectiveness of minimally invasive spleen-preserving surgeries compared to total splenectomy for treating primary splenic hydatidosis in Jordan. Covering 18 patients from January 2015 to June 2021, the research highlights similar recurrence rates between both surgical approaches, emphasizing the benefits of spleen preservation in maintaining immune function and reducing septic risks, particularly in pediatric patients.

Description:

The study delves into a detailed analysis of 18 cases of primary splenic hydatid cysts treated through spleen-preserving surgeries-laparoscopic partial splenectomy, cystectomy, and cyst deroofing-augmented by albendazole therapy. It presents a comprehensive comparison based on patient demographics, symptoms, surgical details, and outcomes, including complications and recurrence rates. Findings reveal no significant statistical difference in recurrence rates between spleen-preserving methods and total splenectomy, suggesting the viability of less invasive approaches for managing this condition effectively while preserving spleen functionality and minimizing post-operative complications. The study underlines the need for individualized treatment plans and further research with larger cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: June 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adult patients (age 14 years or older).

• Diagnosed exclusively with primary, non-recurrent splenic hydatid cysts.

Exclusion Criteria:

• Children under 14 years of age.

• Patients in late pregnancy.

• Individuals with recurrent cysts.

• Cases with extra-splenic involvement.

• Patients with less than two years of postoperative follow-up.

Related Conditions & MeSH terms

• Hydatid Disease
• Minimally Invasive Surgery

Intervention

Procedure:
• Minimally Invasive Surgery
Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.

Locations

Country	Name	City	State
Jordan	Anas Aljaiuossi	Irbid

Sponsors (1)

Lead Sponsor	Collaborator
Yarmouk University

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Postoperative Short-Term Complications	The measure focuses on the incidence and nature of short-term complications following spleen-preserving surgeries compared to total splenectomy. Short-term complications may include infection, bleeding, or any other immediate post-surgical issues that impact recovery.	Up to 1 month post-operation
Primary	Incidence of Postoperative Long-Term Complications	This measure assesses the long-term complications associated with spleen-preserving surgeries versus total splenectomy. Specifically, it examines the recurrence of hydatid cysts as a significant long-term complication.	Up to 2 years post-operation